Equillium (FRA:0FY) Sale Of Investment : €46.36 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Equillium Sale Of Investment?

Equillium's sale of investment for the three months ended in Dec. 2023 was €11.00 Mil. It means Equillium gained €11.00 Mil from selling investments. Equillium's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was €46.36 Mil.

Compared with last quarter (€10.31 Mil in Sep. 2023 ), Equillium gained more money from selling investments in Dec. 2023 (€11.00 Mil).

Equillium Sale Of Investment Historical Data

The historical data trend for Equillium's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Sale Of Investment Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

Get a 7-Day Free Trial

47.27

30.51

53.50

31.36

45.85

Equillium Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sale Of Investment	Get a 7-Day Free Trial															6.59	11.21	13.85	10.31	11.00

Equillium Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €46.36 Mil.

Equillium Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Equillium's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (FRA:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines